SPRINGWORKS THERAPEUTICS, INC. Financials SpringWorks Therapeutics, Inc.
Equities
SWTX
US85205L1070
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.35 USD | -7.45% |
|
-1.92% | +18.77% |
| 02/05 | Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating | MT |
| 02/05 | SpringWorks Therapeutics Shares Fall After Wider-Than-Expected Q1 Loss | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,655 | 3,476 | 3,020 | 1,616 | 2,682 | 3,194 | - | - |
| Enterprise Value (EV) 1 | 1,328 | 2,970 | 2,916 | 1,549 | 2,506 | 3,071 | 2,536 | 2,835 |
| P/E ratio | -10.1 x | -69.1 x | -17.3 x | -4.99 x | -7.09 x | -8.91 x | -10.6 x | -46.6 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 99.3 x | - | - | 492 x | 28.9 x | 11.1 x | 5 x |
| EV / Revenue | - | 84.9 x | - | - | 460 x | 27.7 x | 8.78 x | 4.44 x |
| EV / EBITDA | -22.5 x | -64.6 x | -16.9 x | -5.53 x | -7.34 x | -8.53 x | -11.3 x | -28 x |
| EV / FCF | -27.6 x | -90.5 x | -22.5 x | -9.02 x | -10.9 x | -11.9 x | -12.6 x | - |
| FCF Yield | -3.62% | -1.11% | -4.45% | -11.1% | -9.19% | -8.43% | -7.95% | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 43,006 | 47,931 | 48,727 | 62,137 | 73,480 | 73,680 | - | - |
| Reference price 2 | 38.49 | 72.52 | 61.98 | 26.01 | 36.50 | 43.35 | 43.35 | 43.35 |
| Announcement Date | 12/03/20 | 25/02/21 | 24/02/22 | 28/02/23 | 27/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 35 | - | - | 5.447 | 96.53 | 278 | - |
| EBITDA 1 | -59.05 | -45.98 | -173 | -279.9 | -341.3 | -341.7 | -125.3 | - |
| EBIT 1 | -59.24 | -46.32 | -173.5 | -280.7 | -343 | -363.2 | -200.1 | -100.4 |
| Operating Margin | - | -132.35% | - | - | -6,297.28% | -376.26% | -71.99% | - |
| Earnings before Tax (EBT) 1 | -58.31 | -45.57 | -173.9 | -277.4 | -325.1 | -323.6 | -228.3 | -70.16 |
| Net income 1 | -50.58 | -45.57 | -173.9 | -277.4 | -325.1 | -340 | -245.3 | -70.19 |
| Net margin | - | -130.21% | - | - | -5,968.5% | -352.25% | -88.24% | - |
| EPS 2 | -3.810 | -1.050 | -3.590 | -5.210 | -5.150 | -4.487 | -3.871 | -0.9300 |
| Free Cash Flow 1 | -48.11 | -32.83 | -129.9 | -171.8 | -230.2 | -259 | -201.5 | - |
| FCF margin | - | -93.81% | - | - | -4,225.81% | -268.32% | -72.49% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 12/03/20 | 25/02/21 | 24/02/22 | 28/02/23 | 27/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | 5.447 | 21.01 | 25.77 | 32.42 | 40.07 | - | - |
| EBITDA | -55.65 | -61.36 | -68.82 | -71.53 | -78.2 | -77.45 | -82.47 | - | - | - | - | - | - | - | - |
| EBIT 1 | -55.8 | -61.47 | -69.01 | -71.74 | -78.45 | -77.7 | -82.85 | -84 | -98.46 | -93.93 | -90.42 | -84.61 | -81.18 | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | -1,807.66% | -447.16% | -350.85% | -260.98% | -202.6% | - | - |
| Earnings before Tax (EBT) 1 | -56.07 | -61.8 | -69.05 | -72.39 | -74.18 | -73.42 | -77.92 | -79.44 | -94.32 | -87.38 | -98.11 | -83.72 | -77.61 | - | - |
| Net income 1 | -56.07 | -61.8 | -69.05 | -72.39 | -74.18 | -73.42 | -77.92 | -79.44 | -94.32 | -87.38 | -91.84 | -87.44 | -84.8 | - | - |
| Net margin | - | - | - | - | - | - | - | - | -1,731.63% | -416% | -356.36% | -269.71% | -211.64% | - | - |
| EPS 2 | -1.160 | -1.260 | -1.410 | -1.370 | -1.170 | -1.180 | -1.250 | -1.270 | -1.450 | -1.180 | -1.179 | -1.089 | -1.052 | -1.010 | -0.9700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 24/02/22 | 05/05/22 | 04/08/22 | 03/11/22 | 28/02/23 | 03/05/23 | 02/08/23 | 02/11/23 | 27/02/24 | 02/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 328 | 506 | 104 | 67.5 | 176 | 123 | 658 | 359 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -48.1 | -32.8 | -130 | -172 | -230 | -259 | -202 | - |
| ROE (net income / shareholders' equity) | -38.5% | -8.09% | -35.5% | -56.6% | -54.9% | -54.1% | -118% | - |
| ROA (Net income/ Total Assets) | -30.4% | -10% | -33.8% | -51.2% | -48% | -64.7% | -82.6% | - |
| Assets 1 | 166.2 | 455.5 | 514.3 | 541.4 | 678 | 568.4 | 326.4 | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | - | - | -3.030 | -3.530 | -5.050 | -3.500 | - |
| Capex 1 | 0.67 | 0.64 | 2.02 | 10.2 | 7.39 | 2 | 2 | - |
| Capex / Sales | - | 1.83% | - | - | 135.58% | 1.81% | 0.69% | - |
| Announcement Date | 12/03/20 | 25/02/21 | 24/02/22 | 28/02/23 | 27/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
43.35
USD
Average target price
67.66
USD
Spread / Average Target
+56.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.77% | 3.45B | |
| -1.65% | 104B | |
| +6.75% | 97.47B | |
| +5.71% | 22.25B | |
| -12.60% | 21.68B | |
| -9.70% | 18.2B | |
| -39.98% | 17.02B | |
| -10.17% | 16.36B | |
| +6.12% | 14.39B | |
| +35.47% | 12.37B |
- Stock Market
- Equities
- SWTX Stock
- Financials SpringWorks Therapeutics, Inc.
